Literature DB >> 15693639

The pathophysiology of airway dysfunction.

Dennis E Doherty1.   

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are distinct inflammatory disorders with differing pathophysiologic mechanisms, different clinical courses, and, therefore, distinct treatment strategies. Whereas in asthma airflow limitation is typically episodic and reversible, airflow limitation in COPD is progressive and only partially reversible. In contrast to asthma, which is characterized by an elevated number of eosinophils in the blood and the accumulation of elevated numbers of activated eosinophils, mast cells, and CD4+ T(H)2-lymphocytes in the lungs, the primary inflammatory cells present in the lungs of patients with stable COPD are neutrophils, macrophages, and CD8+ lymphocytes. Bronchoconstriction in COPD is largely regulated by cholinergically mediated vagal tone, and the pathologic processes of COPD further reduce airway patency. Bronchodilators, most notably anticholinergics, are recommended as first-line pharmacologic therapy for COPD. Proper use of inhaled anticholinergic medications has been shown to lead to significant reversibility of acetylcholine-mediated bronchoconstriction during both stable disease and exacerbations of COPD. For patients with asthma, current guidelines recommend anti-inflammatory medications, specifically inhaled corticosteroids and leukotriene-modifiers, as first-line therapy, making these agents the mainstay of asthma therapy. In contrast, the current guidelines for COPD management recommend that inhaled anti-inflammatory agents be tried in patients with COPD only as second-line therapy for patients who have severe to very severe airflow obstruction with frequent exacerbations and who remain symptomatic despite maximized bronchodilation with multiple inhaled bronchodilators. Hence, it is extremely important to understand the differences between the underlying pathogenesis and pathophysiology of COPD and those of asthma, as these differences dictate the implementation of distinctly different treatment options for these 2 diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15693639     DOI: 10.1016/j.amjmed.2004.10.017

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

1.  Exhaled breath analysis: from occupational to respiratory medicine.

Authors:  Massimo Corradi; Antonio Mutti
Journal:  Acta Biomed       Date:  2005

2.  Persistent effects induced by IL-13 in the lung.

Authors:  Patricia C Fulkerson; Christine A Fischetti; Lynn M Hassman; Nikolaos M Nikolaidis; Marc E Rothenberg
Journal:  Am J Respir Cell Mol Biol       Date:  2006-04-27       Impact factor: 6.914

3.  Chronic respiratory symptoms in Croatian Adriatic island metapopulations.

Authors:  Eugenija Zuskin; Nina Smolej Narancić; Tatjana Skarić-Jurić; Maja Barbalić; Pavao Rudan; Mirjana Kujundzić-Tiljak; Jasna Pucarin-Cvetković; E Neil Schachter
Journal:  Croat Med J       Date:  2006-08       Impact factor: 1.351

4.  Human eosinophils express RAGE, produce RAGE ligands, exhibit PKC-delta phosphorylation and enhanced viability in response to the RAGE ligand, S100B.

Authors:  Colleen S Curran; Paul J Bertics
Journal:  Int Immunol       Date:  2011-10-24       Impact factor: 4.823

Review 5.  What can computed tomography and magnetic resonance imaging tell us about ventilation?

Authors:  Brett A Simon; David W Kaczka; Alexander A Bankier; Grace Parraga
Journal:  J Appl Physiol (1985)       Date:  2012-05-31

Review 6.  Bronchial thermoplasty for the treatment of asthma.

Authors:  Neil Martin; Ian D Pavord
Journal:  Curr Allergy Asthma Rep       Date:  2009-01       Impact factor: 4.806

Review 7.  GOLD in Practice: Chronic Obstructive Pulmonary Disease Treatment and Management in the Primary Care Setting.

Authors:  Barbara P Yawn; Matthew L Mintz; Dennis E Doherty
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-02-12

8.  Airway smooth muscle hypercontractility in asthma.

Authors:  Rachid Berair; Fay Hollins; Christopher Brightling
Journal:  J Allergy (Cairo)       Date:  2013-03-18

9.  Multiple facets of cAMP signalling and physiological impact: cAMP compartmentalization in the lung.

Authors:  Anouk Oldenburger; Harm Maarsingh; Martina Schmidt
Journal:  Pharmaceuticals (Basel)       Date:  2012-11-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.